How much profit has Genomed made this year?
Genomed has made 926,250 PLN this year.
Genomed Net Income 2024
Genomed Net Income
926,250 PLN
Ticker
GEN.WA
ISIN
PLGNOMD00024
In 2024, Genomed's profit amounted to 926,250 PLN, a 174.07% increase from the 337,960 PLN profit recorded in the previous year.
The Genomed Net Income history
| YEAR | NET INCOME (undefined PLN) |
|---|---|
| 2023 | 0.93 |
| 2022 | 0.34 |
| 2021 | 1.24 |
| 2020 | 0.41 |
| 2019 | 1 |
| 2018 | 1.48 |
| 2017 | 1.8 |
| 2016 | 0.27 |
| 2015 | 0 |
Genomed Revenue, EBIT, Net Income PLGNOMD00024 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Genomed, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Genomed from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Genomed’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Genomed. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Genomed’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Genomed’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Genomed’s growth potential.
Genomed Revenue, EBIT and net profit per share
| Date | Genomed Revenue | Genomed EBIT | Genomed Net Income |
|---|---|---|---|
| 2023 | 22.48 M undefined | 1.24 M undefined | 926,250 undefined |
| 2022 | 20.46 M undefined | 356,550 undefined | 337,960 undefined |
| 2021 | 19.89 M undefined | 1.34 M undefined | 1.24 M undefined |
| 2020 | 18.75 M undefined | 467,730 undefined | 412,260 undefined |
| 2019 | 19.67 M undefined | 1.08 M undefined | 1 M undefined |
| 2018 | 18.59 M undefined | 1.82 M undefined | 1.48 M undefined |
| 2017 | 16.36 M undefined | 2.23 M undefined | 1.8 M undefined |
| 2016 | 14.39 M undefined | 323,000 undefined | 271,470 undefined |
| 2015 | 9.68 M undefined | 19,060 undefined | 4,140 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2015 | 9.68 M PLN | 19,060 PLN | 4,140 PLN |
| 2016 | 14.39 M PLN | 323,000 PLN | 271,470 PLN |
| 2017 | 16.36 M PLN | 2.23 M PLN | 1.8 M PLN |
| 2018 | 18.59 M PLN | 1.82 M PLN | 1.48 M PLN |
| 2019 | 19.67 M PLN | 1.08 M PLN | 1 M PLN |
| 2020 | 18.75 M PLN | 467,730 PLN | 412,260 PLN |
| 2021 | 19.89 M PLN | 1.34 M PLN | 1.24 M PLN |
| 2022 | 20.46 M PLN | 356,550 PLN | 337,960 PLN |
| 2023 | 22.48 M PLN | 1.24 M PLN | 926,250 PLN |
Genomed stock margins PLGNOMD00024 ·
The Genomed margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Genomed. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Genomed.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Genomed's sales revenue. A higher gross margin percentage indicates that the Genomed retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Genomed's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Genomed's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Genomed's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Genomed. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Genomed's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Genomed Margin History
| Genomed Gross margin | Genomed Profit margin | Genomed EBIT margin | Genomed Profit margin |
|---|---|---|---|
| 2023 | 42.71 % | 5.53 % | 4.12 % |
| 2022 | 38.18 % | 1.74 % | 1.65 % |
| 2021 | 39.11 % | 6.72 % | 6.22 % |
| 2020 | 35.27 % | 2.49 % | 2.2 % |
| 2019 | 36.62 % | 5.47 % | 5.09 % |
| 2018 | 32.94 % | 9.77 % | 7.96 % |
| 2017 | 37.3 % | 13.65 % | 11.01 % |
| 2016 | 31.34 % | 2.24 % | 1.89 % |
| 2015 | 29 % | 0.2 % | 0.04 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2015 | 29 % | 0.2 % | 0.04 % |
| 2016 | 31.34 % | 2.24 % | 1.89 % |
| 2017 | 37.3 % | 13.65 % | 11.01 % |
| 2018 | 32.94 % | 9.77 % | 7.96 % |
| 2019 | 36.62 % | 5.47 % | 5.09 % |
| 2020 | 35.27 % | 2.49 % | 2.2 % |
| 2021 | 39.11 % | 6.72 % | 6.22 % |
| 2022 | 38.18 % | 1.74 % | 1.65 % |
| 2023 | 42.71 % | 5.53 % | 4.12 % |
Genomed Aktienanalyse
What does Genomed do?
Genomed ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Genomed's Profit Margins
The profit margins of Genomed represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Genomed's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Genomed's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Genomed's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Genomed’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Genomed stock
How has the profit developed compared to last year?
The profit has increased by 174.07% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Genomed publish its earnings?
Genomed publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Genomed?
The profits of Genomed are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Genomed?
You can learn more about the earnings of Genomed by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Genomed pay?
Over the past 12 months, Genomed paid a dividend of 1 PLN . This corresponds to a dividend yield of about 3.82 %. For the coming 12 months, Genomed is expected to pay a dividend of 0 PLN.
What is the dividend yield of Genomed?
The current dividend yield of Genomed is 3.82 %.
When does Genomed pay dividends?
Genomed pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Genomed?
Genomed paid dividends every year for the past 0 years.
What is the dividend of Genomed?
For the upcoming 12 months, dividends amounting to 0 PLN are expected. This corresponds to a dividend yield of 0 %.
In which sector is Genomed located?
Genomed is assigned to the 'Health' sector.
Wann musste ich die Aktien von Genomed kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Genomed from 8/16/2019 amounting to 1 PLN, you needed to have the stock in your portfolio before the ex-date on 7/2/2019.
When did Genomed pay the last dividend?
The last dividend was paid out on 8/16/2019.
What was the dividend of Genomed in the year 2023?
In the year 2023, Genomed distributed 0 PLN as dividends.
In which currency does Genomed pay out the dividend?
The dividends of Genomed are distributed in PLN.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Genomed
Our stock analysis for Genomed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genomed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.